Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)

NCT04555213 is registered in ClinicalTrials.gov with Noxopharm Limited as lead sponsor.

NCT NCT04555213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04555213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)
Lead sponsor
Noxopharm Limited
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2020
Completion date
August 10, 2021
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19